THALLOUS CHLORIDE TI-201 INJECTION SOLUTION

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

THALLIUM CHLORIDE(TI 201)

Disponible depuis:

CURIUM CANADA INC

Code ATC:

V09GX01

DCI (Dénomination commune internationale):

THALLIUM 201 TL CHLORIDE

Dosage:

37MBq

forme pharmaceutique:

SOLUTION

Composition:

THALLIUM CHLORIDE(TI 201) 37MBq

Mode d'administration:

INTRAVENOUS

Unités en paquet:

10ML

Type d'ordonnance:

Schedule C

Domaine thérapeutique:

ROENTGENOGRAPHY

Descriptif du produit:

Active ingredient group (AIG) number: 0152598004; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2018-12-07

Résumé des caractéristiques du produit

_Page 1 of 21 _
PRODUCT MONOGRAPH
THALLOUS CHLORIDE TL 201 INJECTION
Thallium Tl 201
Solution for intravenous use containing per mL, 37 megabecquerels (1
millicurie)
Thallous Chloride Tl 201 at calibration time.
Radiodiagnostic Agent
Curium Canada Inc.
2572 boul. Daniel-Johnson, Suite 245-249
Laval, QC, H7T-2R3
CANADA
Date of Revision: April 26
th
, 2019
CONTROL NUMBER: 225111
_Page 2 of 21 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
DESCRIPTION...................................................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
5
CONTRAINDICATIONS
..................................................................................................
6
WARNINGS AND PRECAUTIONS
.................................................................................
6
ADVERSE REACTIONS
...................................................................................................
9
DRUG INTERACTIONS
...................................................................................................
9
DOSAGE AND ADMINISTRATION
.............................................................................
10
RADIATION DOSIMETRY
............................................................................................
12
OVERDOSAGE
...............................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 13
STORAGE AND STABILITY
.........................................................................................
14
SPECIAL HANDLING INSTRUCTIONS
......................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................